Europe Glycomic Therapeutics Market Forecast to 2028

Report Code : BMIRE00027510 | Region : Europe | Industry : Pharmaceuticals | Published Date : 18/Nov/2022
Europe Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

The glycomic therapeutics market in Europe is expected to grow from US$ 37,002.34 million in 2022 to US$ 88,658.62 million by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028.

Increasing Research and Development in Glycomic Therapeutics Drives Market Growth

Glycans may be exceedingly complex and are found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. For instance, in March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients suffering from an advanced stage of cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans. In April 2022, CPTAC glycoproteomic researchers developed the "Peptide-First" multi-attribute glycan identification method. According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animal through glycomics studies. Such research and developments in the field of glycomics are driving the glycomics therapeutics market growth.

Market Overview

The Europe glycomic therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the glycomic therapeutics market. Europe occupies a significant position in the glycomic therapeutics market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to the rising number of cancer cases and viral infection and an increase in investment in research and development.

Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Europe Glycomic Therapeutics Market Segmentation

The Europe glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Europe glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Europe glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Europe glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Europe glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Europe glycomic therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. Intellihep Ltd; BioMarin Pharmaceutical Inc.; Genzyme Corporation(Sanofi); Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in Europe.

The List of Companies - Europe Glycomic Therapeutics Market

● Intellihep Ltd                                                      

● BioMarin Pharmaceutical Inc.                    

● Genzyme Corporation (Sanofi)                 

● Bayer AG                                                            

● GlycoMar                                                           

● GlaxoSmithKline plc.           

● F. Hoffmann-La Roche Ltd

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Glycomic Therapeutics Market – By Class

1.3.2 Europe Glycomic Therapeutics Market – By Structures

1.3.3 Europe Glycomic Therapeutics Market – By Indications

1.3.4 Europe Glycomic Therapeutics Market – By Mode of Action

1.3.5 Europe Glycomic Therapeutics Market – By Country

2. Europe Glycomic Therapeutics Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Glycomic Therapeutics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe – PEST Analysis

4.3 Expert Opinion

5. Europe Glycomic Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes

5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

5.2 Market Restraints

5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

5.3 Market Opportunities

5.3.1 Wide Applications of Glycomics in Therapeutics

5.4 Future Trends

5.4.1 New Tools in Glycomics Research

5.5 Impact Analysis

6. Glycomic Therapeutics Market– Europe Analysis

6.1 Europe Glycomic Therapeutics Market Revenue Forecast and Analysis

7. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class

7.1 Overview

7.2 Europe Glycomic Therapeutics Market, By Class 2022 & 2028 (%)

7.2.1 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

7.3 Isolated

7.3.1 Overview

7.3.2 Europe Isolated Revenue and Forecast to 2028 (US$ Million)

7.4 Synthetic

7.4.1 Overview

7.4.2 Europe Synthetic - Revenue and Forecast to 2028 (US$ Million)

8. Europe Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication

8.1 Overview

8.2 Europe Glycomics Market, By Indication 2022 & 2028 (%)

8.2.1 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

8.3 Thrombosis and Chemoprophylaxis

8.3.1 Overview

8.3.2 Europe Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)

8.4 Anaemia

8.4.1 Overview

8.4.2 Europe Anaemia Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-adhesive and Anti-inflammatory

8.5.1 Overview

8.5.2 Europe Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)

8.6 Cataract

8.6.1 Overview

8.6.2 Europe Cataract Revenue and Forecast to 2028 (US$ Million)

8.7 Gaucher’s diseases

8.7.1 Overview

8.7.2 Europe Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)

8.8 MPS-1 & IV

8.8.1 Overview

8.8.2 Europe MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)

8.9 Cancer

8.9.1 Overview

8.9.2 Europe Cancer Revenue and Forecast to 2028 (US$ Million)

8.10 Alzheimer's

8.10.1 Overview

8.10.2 Europe Alzheimer's Revenue and Forecast to 2028 (US$ Million)

8.11 Influenza Type A and B

8.11.1 Overview

8.11.2 Europe Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Europe Others Revenue and Forecast to 2028 (US$ Million)

9. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures

9.1 Overview

9.2 Europe Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)

9.2.1 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

9.2.1.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

9.2.1.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

9.2.1.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

9.2.1.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 Europe Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 Europe Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.4 Europe Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.4.5 Oseltamivir

9.4.5.1 Overview

9.4.5.2 Europe Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 Europe Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 Europe Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 Europe Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 Europe Heparin - Market Revenue and Forecast to 2028 (US$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 Europe Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 Europe Laronidase - Market Revenue and Forecast to 2028 (US$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 Europe Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 Europe Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 Europe Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

9.8.3.2 Europe Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.3 Agalsidase (Fabrazyme)

9.8.3.3.1 Overview

9.8.3.3.2 Europe Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.4 N-butyl-deoxynojirimycin (DNJ)

9.8.3.4.1 Overview

9.8.3.5 Europe N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.4 Others

9.8.4.1 Overview

9.8.4.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9 Others

9.9.1 Overview

9.9.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3 Acarbose

9.9.3.1 Overview

9.9.3.2 Europe Acarbose - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.3 Alglucosidase Alfa (Myozyme)

9.9.3.3.1 Overview

9.9.3.3.2 Europe Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.4 Allosamidin

9.9.3.4.1 Overview

9.9.3.4.2 Europe Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)

9.9.4 Others

9.9.4.1 Overview

9.9.4.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)

10. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action

10.1 Overview

10.2 Europe Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)

10.2.1 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

10.3 Inhibits Neuraminidase

10.3.1 Overview

10.3.2 Europe Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)

10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate

10.4.1 Overview

10.4.2 Europe Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)

10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

10.5.1 Overview

10.5.2 Europe Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)

10.6 Tissue Plasminogen Activator

10.6.1 Overview

10.6.2 Europe Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

10.7 Inhibits Glucosylceramide Synthase

10.7.1 Overview

10.7.2 Europe Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

10.8 Interleukin 1 And 2 And 3

10.8.1 Overview

10.8.2 Europe Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

10.9 Beta And Gamma Interferons

10.9.1 Overview

10.9.2 Europe Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)

10.10 Others

10.10.1 Overview

10.10.2 Europe Others- Market Revenue And Forecasts To 2028 (US$ Million)

11. Europe Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Europe: Glycomic Therapeutics Market

11.1.1 Overview

11.1.2 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.3 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.3.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.3.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.3.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.3.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.4 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.5 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6 Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.1.6.1 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.1.1 Overview

11.1.6.1.2 Germany: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.1.3 Germany: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.1.4 Germany: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.1.4.1 Germany: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.1.4.2 Germany: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.6.1.4.3 Germany: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.6.1.4.4 Germany: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.1.5 Germany: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.1.6 Germany: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.2.1 Overview

11.1.6.2.2 UK: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.2.3 UK: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.2.4 UK: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.2.4.1 UK: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.2.4.2 UK: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.6.2.4.3 UK: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.6.2.4.4 UK: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.2.5 UK: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.2.6 UK: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6.3 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.3.1 Overview

11.1.6.3.2 France: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.3.3 France: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.3.4 France: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.3.4.1 France: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.3.4.2 France: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.6.3.4.3 France: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.6.3.4.4 France: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.3.5 France: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.3.6 France: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6.4 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.4.1 Overview

11.1.6.4.2 Italy: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.4.3 Italy: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.4.4 Italy: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.4.4.1 Italy: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.4.4.2 Italy: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.6.4.4.3 Italy: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.6.4.4.4 Italy: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.4.5 Italy: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.4.6 Italy: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6.5 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.5.1 Overview

11.1.6.5.2 Spain: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.5.3 Spain: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.5.4 Spain: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.5.4.1 Spain: Glycomic Therapeutics Market, by Targeting Glycosphingolipid, 2019-2028 (US$ Million)

11.1.6.5.4.2 Spain: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.5.4.3 Spain: Glycomic Therapeutics Market, by Targeting Glycosaminoglycans, 2019-2028 (US$ Million)

11.1.6.5.4.4 Spain: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.5.5 Spain: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.5.6 Spain: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.6.6 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.6.1 Overview

11.1.6.6.2 Rest of Europe: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.6.3 Rest of Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.6.6.4 Rest of Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.6.6.4.1 Rest of Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.6.6.4.2 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.6.6.4.3 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.6.6.4.4 Rest of Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.6.6.5 Rest of Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.6.6.6 Rest of Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

12. Glycomic Therapeutics Market –Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Glycomic Therapeutics Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 Intellihep Ltd

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 BioMarin Pharmaceutical Inc.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Genzyme Corporation (Sanofi)

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Bayer AG

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 GlycoMar

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 GlaxoSmithKline plc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 F. Hoffmann-La Roche Ltd

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES.

Table 1. Europe Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 2. Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 3. Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 4. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 5. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 6. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 7. Europe Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 8. Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 9. Europe Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 10. Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 11. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 12. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 13. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 14. Europe Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 15. Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 16. Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 17. Germany Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 19. Germany Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 20. Germany Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 21. Germany Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 22. Germany Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 23. Germany Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 24. Germany Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 25. UK Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 26. UK Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 27. UK Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 28. UK Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 29. UK Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 30. UK Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 31. UK Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 32. UK Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 33. France Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 34. France Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 35. France Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 36. France Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 37. France Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 38. France Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 39. France Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 40. France Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 41. Italy Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 42. Italy Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 43. Italy Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 44. Italy Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 45. Italy Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 46. Italy Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 47. Italy Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 48. Italy Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 49. Spain Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 50. Spain Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 51. Spain Glycomic Therapeutics Market, by Targeting Glycosphingolipid – Revenue and Forecast to 2028 (US$ Million)

Table 52. Spain Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 53. Spain Glycomic Therapeutics Market, by Targeting Glycosaminoglycans – Revenue and Forecast to 2028 (US$ Million)

Table 54. Spain Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 55. Spain Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 56. Spain Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 57. Rest of Europe Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 58. Rest of Europe Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 59. Rest of Europe Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 60. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 61. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 62. Rest of Europe Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 63. Rest of Europe Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 64. Rest of Europe Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 65. Organic Developments in the Glycomic Therapeutics Market

Table 66. Inorganic Developments in the Glycomic Therapeutics Market

Table 67. Glossary of Terms in Glycomic Therapeutics Market

The List of Companies - Europe Glycomic Therapeutics Market

● Intellihep Ltd                                                      

● BioMarin Pharmaceutical Inc.                    

● Genzyme Corporation (Sanofi)                 

● Bayer AG                                                            

● GlycoMar                                                           

● GlaxoSmithKline plc.           

● F. Hoffmann-La Roche Ltd

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Glycomic Therapeutics Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in Europe Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Europe Glycomic Therapeutics Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry